SEC filingsOct 12, 2026 to Oct 19, 2026: insiders reported 840 purchases and sales across 212 companies.840 insider purchases and sales in 7 daysSee the filings →
HornScout

Company profile

BCAX

Bicara Therapeutics Inc.
NASDAQHealth Care

Latest close: 16.78 USD · Oct 16, 2026 · 1 year · split-adjusted

On the price, the facts of the public record■Insider buy□Insider sell◇Significant stake declared (13D)●Results filed
With an account, also○dividends▲splits◌next earningswith an account

End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.

Latest on record

The most recent facts, as filed.

Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.

  1. Sep 8, 2026Reported sale · Form 4Ryan Cohlhepp, President, COO & Interim CEO · $320.1KOpen the filing ↗
  2. Sep 8, 2026Reported sale · Form 4Ryan Cohlhepp, President, COO & Interim CEO · $80.7KOpen the filing ↗
  3. Sep 8, 2026Notice of sale · Form 144Hyep Ivan · Officer · $283.0KOpen the filing ↗

In numbers

What this profile holds, counted.

Closes · 1 year250
SEC filings on record24621 flagged findings
Reported transactions (Form 4)80since Mar 4, 2026 · and 40 other holdings
Corporate events (8-K)4since Jun 6, 2025

What the record says

Description, identity and filings, each with its source.

Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.

SEC topics

Regulatory history

Topics detected in its SEC reports, with the original excerpt.

Each topic is assigned by a classifier over the full filing; the excerpts show where it was detected and are not always enough to verify it. Open the filing to read it in full.

  • 2026-05-11share offering or dilution eventrecentOpen filing ↗
    “…revenue from product sales. The Company historically has funded its operations from the issuance of common stock in…”
    +1 more passage from the same document
    • “…personnel and providing general and administrative support for these operations. To date, we have funded our operations primarily…”
  • 2026-05-11listing compliance noticerecentOpen filing ↗
    “…be more or less favorable to us than our stockholders. We may not be able to satisfy listing requirements of Nasdaq or maintain a…”
  • 2026-03-30share offering or dilution eventrecentOpen filing ↗
    “…the net proceeds from our IPO, sales of our common stock under our ATM Program, marketable securities, equity financings, or…”
    +1 more passage from the same document
    • “…common stock under our ATM Program, marketable securities, equity financings, or any future equity or debt financings and upfront…”
  • 2026-03-30listing compliance noticerecentOpen filing ↗
    “…be more or less favorable to us than our stockholders. We may not be able to satisfy listing requirements of Nasdaq or maintain a…”
  • 2026-03-30capital return (buybacks/dividends)recentOpen filing ↗
    “…be held in trust by other entities. Dividends We have never declared or paid any cash dividends on our common shares. We do not…”

Original excerpts from SEC filings, untranslated. Not advice and not a prediction.

Reverse splits in 5 years

1 reverse split in 5 years (1:9.24 on Sep 30, 2024) · 1:9.24 cumulative

The other times: of 818 securities that did their first reverse split in 5 years, a year later the median was worth 0.53× the price on the day of the split; 382 lost more than half and 209 rose (809 with a price a year later).

Our own series, not the whole market: based on the splits we have on record (provider and SEC); an unrecorded one does not count. Historical distribution, not a prediction.

SEC record

SEC dossier

What this company has filed with the SEC, in plain language.

The 25 most recent filings (of 246)

Everything filed

Every SEC filing, newest first, with what it is. Below, each type with its own explanation.

  • Oct 7, 26SCHEDULE 13G/A ↗Passive stake · T. Rowe Price Investment Management, Inc. · 4.2% · event on Sep 30, 26 · amendment
  • Sep 10, 26Form 4 ↗Insider transaction
  • Notice of proposed sale · 2 Form 144 filingsshow all 2hide
  • Aug 25, 268-K ↗Current report · Entered a material agreement
  • Aug 14, 26Form 4 ↗Insider transaction
  • Aug 14, 26Form 3 ↗Insider transaction
  • Aug 13, 26SCHEDULE 13G/A ↗Passive stake · JANUS HENDERSON GROUP Ltd. · 4.8% · event on Jun 30, 26 · amendment
  • Insider transaction · 3 Form 4 filingsshow all 3hide
  • Aug 11, 2610-Q ↗Quarterly report
  • Aug 11, 268-K ↗Current report · Results
  • Notice of proposed sale · 3 Form 144 filingsshow all 3hide
  • Insider transaction · 2 Form 4 filingsshow all 2hide
  • Insider transaction · 2 Form 3 filingsshow all 2hide
  • Jul 28, 268-K ↗Current report · A senior executive left or was appointed
  • Jul 27, 26SCHEDULE 13G ↗Passive stake · BlackRock, Inc. · 5.4% · event on Jun 30, 26
  • Jul 14, 26Form 4 ↗Insider transaction
  • Jul 10, 26Form 144 ↗Notice of proposed sale
  • Jul 10, 26Form 4 ↗Insider transaction

246 filings on record, the oldest from Jul 5, 24.

Listing the 25 most recent filings of the 246 on record.

8-Ks, explained

Structure3Governance1
  • Aug 25, 26StructureEntered a material agreement+1 more in the same filing8-K 1.01 ↗
  • Jul 28, 26GovernanceA senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
  • Feb 26, 26StructureEntered a material agreement+2 more in the same filing8-K 1.01 ↗
  • Jun 6, 25StructureEntered a material agreement+1 more in the same filing8-K 1.01 ↗

Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.

Ownership and control

Schedule 13D: stake and stated purpose

Filed by holders above 5% of a share class who cannot use the short form. It includes the investor's stated purpose: read it before assuming they seek influence.

  • RA Capital Management, L.P.11.5%Feb 26, 26SCHEDULE 13D/A ↗4 co-filers on this document — the figure is the largest single stake, not their sum.

Schedule 13G: short-form filing

The short form, for holders who meet specific requirements: institutional investors, passive investors without a control purpose, or exempt investors. Asset managers and index funds usually file it.

  • Raymond Debbane9.6%Jun 30, 25SCHEDULE 13G/A ↗8 co-filers on this document — the figure is the largest single stake, not their sum.
  • Vestal Point Capital, LP8.3%Mar 31, 26SCHEDULE 13G/A ↗2 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
  • Deep Track Capital, LP6.2%Mar 31, 26SCHEDULE 13G/A ↗3 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
  • BlackRock, Inc.5.4%Jun 30, 26SCHEDULE 13G ↗
  • JANUS HENDERSON GROUP Ltd.4.8%Jun 30, 26SCHEDULE 13G/A ↗1 earlier filing
show 3 more holdershide
  • Red Tree GP, LLC4.8%Mar 31, 26SCHEDULE 13G/A ↗3 co-filers on this document — the figure is the largest single stake, not their sum.
  • T. Rowe Price Investment Management, Inc.4.2%Sep 30, 26SCHEDULE 13G/A ↗2 earlier filings
  • FMR LLC3.2%Mar 31, 26SCHEDULE 13G/A ↗2 co-filers on this document — the figure is the largest single stake, not their sum. · 2 earlier filings

Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.

Sale intention announced

On Sep 8, Hyep Ivan filed notice of intent to sell up to $283K. That is about 0.02% of shares outstanding. It is filed under a scheduled plan (10b5-1), arranged in advance.

A notice is not a sale: it may not go ahead, may happen in part, or at a different price.

No sale of theirs is on record yet in Form 4; the 90-day window is still open.

View notice (Form 144) ↗+9 more recent notices · 7 with a later sale

SEC record

Insider transactions

Buys and sells reported by officers, directors and major shareholders on SEC Form 4.

Buys and sells

  • Sep 8, 26Sell$320KRyan CohlheppPresident, COO & Interim CEO↗
  • Sep 8, 26Sell$81KRyan CohlheppPresident, COO & Interim CEO↗
  • Aug 10, 26Sell$525KRyan CohlheppPresident and COO↗
  • Aug 10, 26Sell$280KClaire MazumdarChief Executive Officer↗
  • Aug 10, 26Sell$350KIvan HyepChief Financial Officer↗
  • Jul 10, 26Sell$283KClaire MazumdarChief Executive Officer↗
  • Jul 10, 26Sell$831Claire MazumdarChief Executive Officer↗
  • Jul 9, 26Sell$16KRyan CohlheppPresident and COO↗
  • Jul 8, 26Sell$651KIvan HyepChief Financial Officer↗
  • Jul 8, 26Sell$132KIvan HyepChief Financial Officer↗
  • Jul 8, 26Sell$25KIvan HyepChief Financial Officer↗
  • Jul 8, 26Sell$657KRyan CohlheppPresident and COO↗

There are 11 more transactions in this stretch.

Stock compensation, tax and giftsshow the 17 other transactionshide

Stock compensation, tax withholding, option exercises and gifts. They are listed separately and are not included in the purchase and sale totals. The type describes the transaction, not the filer's intent.

  • Sep 8, 26Compensation$66KRyan CohlheppPresident, COO & Interim CEO↗
  • Aug 10, 26Compensation$71KRyan CohlheppPresident and COO↗
  • Aug 10, 26Compensation$38KClaire MazumdarChief Executive Officer↗
  • Aug 10, 26Compensation$47KIvan HyepChief Financial Officer↗
  • Jul 10, 26Compensation$38KClaire MazumdarChief Executive Officer↗
  • Jul 8, 26Compensation$47KIvan HyepChief Financial Officer↗
  • Jul 8, 26Compensation$71KRyan CohlheppPresident and COO↗
  • May 21, 26Compensation$35KIvan HyepChief Financial Officer↗
  • May 18, 26Compensation$57KClaire MazumdarChief Executive Officer↗
  • May 15, 26Compensation$30KRyan CohlheppPresident and COO↗
  • Apr 27, 26Compensation$21KDavid RabenChief Medical Officer↗
  • Apr 21, 26Compensation$35KIvan HyepChief Financial Officer↗
  • Apr 20, 26Compensation$57KClaire MazumdarChief Executive Officer↗
  • Apr 16, 26Compensation$36KClaire MazumdarChief Executive Officer↗
  • Apr 16, 26Compensation$28KClaire MazumdarChief Executive Officer↗
  • Apr 16, 26Compensation$39KClaire MazumdarChief Executive Officer↗
  • Apr 15, 26Compensation$30KRyan CohlheppPresident and COO↗

The full record holds 160 transactions and goes back to Sep 12, 24.

Its sector and its market

Bicara Therapeutics Inc. among Health Care companies

The profile shows what is on record. Context and Radar place the company among those of its sector and region.

With an account you also get

  • The four engines — growth, trend, risk and context — each with its word and its score.
  • The risk band and the sector phase.
  • The company's fundamentals and accounts.
  • Watchlist: your list of companies, with the «since you follow it» figure.

The research continues

The profile tells the story. The market sets the scene.

From Bicara Therapeutics Inc., the path continues in the other areas. Each one is shown with its own example, named in its step.

  1. Place it in its market

    Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.

    See how Context works →
  2. See what deserves a closer look

    Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.

    See how Radar works →
  3. Keep the why

    Follow Bicara Therapeutics Inc. in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.

    See an example review →

Coverage

What sits behind this page.

Where each figure comes from and how far it reaches.

Prices
End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
Series quality
250 clean closes in the period.
SEC records
246 documents on file, from Jul 5, 2024 to Oct 7, 2026.
Company description
No description available.
This page
Generated on Oct 19, 2026; refreshed through the day.

Start at your own pace

Explore first. Go deeper with access.

Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.

Compare plans →
  • No account

    This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.

  • Pro

    What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.

  • Pro+

    Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.

Are the prices real time?

No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.

Which SEC documents appear here?

Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.

Why does a European company show no SEC records?

It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.

Before forming a view on a company,
read what is on record.

One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.

Access by invitation while the beta lasts. Not advice: the profile shows what is on record; it does not recommend.